Cipla

9th January 2017

To,

(a) BSE Limited
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

(b) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai-400 051

(c) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

Please find enclosed Press Release titled as "Cipla appoints Peter Lankau as an Independent Director on its Board".

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary

Encl: as above

Press Release

Cipla appoints Peter Lankau as an Independent Director on its Board

Mumbai, January 9, 2017: Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is delighted to announce the appointment of Mr. Peter Lankau as an independent director on its board with effect from 10th January 2017.

Mr. Lankau has graduated with Bachelors of Science in Biology from the State University of New York at Albany, USA. He has over 30 years of management experience in developing and commercializing pharmaceutical products.

Mr. Lankau is currently a principal of Lankau Consulting LLC. He was previously Executive Chairman of the Board for Nautilus Neurosciences, Inc., Chairman & CEO of Logical Therapeutics, Inc. and President & CEO of Endo Pharmaceuticals Inc. Prior to Endo Pharmaceuticals Inc., he was VP, Sales and Marketing for Alpharma, Inc. He began his pharmaceutical career with Rhone-Poulenc Rorer, Inc. (now Sanofi).

Mr. Lankau currently serves on the Board of Directors of ANI Pharmaceuticals, Inc. and Phosphagenics Limited and also on the Board of Advisors of Orchard Venture Partners, a life sciences venture capital firm.

Welcoming his appointment as an independent director, Dr. Y. K. Hamied, Non-Executive Chairman, Cipla Limited said: "Mr. Lankau brings with him a deep understanding of the US Pharmaceutical market that will help us steer the future thinking of our Company for this focus market."

Mr. Peter Lankau said: "I am delighted to join the Cipla Board, a Company that has had such an inspiring history and bold dreams for its future."

About Cipla Ltd.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. In the last 80+ years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla's research and development focuses on developing innovative products and drug delivery systems.

Media Contacts:
Corporate Communications
Pallavi Golar
E Mail: pallavi.golar@cipla.com

Investor Relations
Alpesh Dalal
E-Mail: Investor.Relations@cipla.com